在现实实践中利用干扰素-β-1a治疗复发性复发性多发性硬化症
M Moccia1, L Santoni, I Vaccari
1Multiple Sclerosis Unit, Policlinico Federico II University Hospital of Naples, Naples, Italy. marcello.moccia@unina.it.
European review for medical and pharmacological sciences
|January 18, 2024
概括
与其他注射疗法相比,干扰素β-1a (PEG-IFN-β-1a) 在复发性复发性多发性硬化症 (RRMS) 患者中显示出更高的坚持率和更低的升级率. 这表明这种较新的干扰素β配方在现实世界中得到了更好的利用.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 现实世界的证据研究研究.
背景情况:
- 干扰素β-1a (PEG-IFN-β-1a) 是治疗复发性复发性多发性硬化症 (RRMS) 的最新进展.
- 与现有的注射性疾病修饰疗法 (DMT) 相比,了解其现实世界的利用对于临床实践至关重要.
研究的目的:
- 描述在RRMS患者中PEG-IFN-β-1a的实际使用情况.
- 为了比较PEG-IFN-β-1a与glatiramer酸盐和皮下干扰素β-1a (SC IFN-β-1a) 在坚持,治疗升级,住院和成本方面.
主要方法:
- 一项基于人口的研究,使用来自意大利坎帕尼亚地区的2015-2019年医疗保健数据.
- 包括RRMS患者新处方PEG-IFN-β-1a,glatiramer乙酸或SC IFN-β-1a.
- 使用混合效应线性和考克斯回归模型分析坚持 (MPR),DMT升级率,住院率和入院成本.
主要成果:
- 与格拉蒂拉默酸盐 (0.91±0.1) 和SC IFN-β-1a (0.92±0.1) 相比,PEG-IFN-β-1a的粘附性更高 (MPR=1.01±0.1).与格拉蒂拉默酸盐 (0.91±0.1) 和SC IFN-β-1a (0.92±0.1) 相比,PEG-IFN-β-1a的粘附性更高.
- 升级到更有效的DMT对于PEG-IFN-β-1a (4.9%) 与格拉蒂拉美尔酸盐 (14.9%) 和SC IFN-β-1a (9.1%) 相比显著较低.
- 没有观察到医院住院率的显著差异,但glatiramer酸盐造成了更高的MS入院费用.
结论:
- 在RRMS患者中,PEG-IFN-β-1a与优异的坚持和减少治疗升级有关.
- 格拉提拉默酸盐最好用于老年,残疾患者.
- 现实数据支持PEG-IFN-β-1a作为RRMS管理中的一个有价值的选择,可能降低与治疗变化相关的医疗保健成本.
更多相关视频
10:46A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
10.7K
08:40Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
4.1K
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...